Senior / Principal Scientist, ADC Conjugation Process Development

Company Overview

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.

Position Overview

We are seeking an experienced and motivated Senior/Principal Scientist in ADC Conjugation Process Development to support our growing pipeline. This role will be responsible for the optimization of critical conjugation and purification process parameters for ADC Drug Substance (DS) Development. The preferred candidate will coordinate and execute strategies from milligram to multi-gram scales, including tox/GMP batches, while demonstrating practical expertise in different methodologies and purification strategies for clinical and commercial-stage ADC DS manufacturing. The ideal candidate will have experience with technology transfer, regulatory compliance, and coordination with CDMO partners at GMP manufacturing facilities. A strong working knowledge of different conjugation technologies and cytotoxic linker-payloads is essential, as is experience with standard analytical and characterization approaches used for both biologics and ADCs.

Responsibilities

• Implement and execute ADC Conjugation Process Development (PD) strategies, including Design of Experiment (DOE) and One Factor at a Time (OFAT) approaches for critical reaction parameters.

• Oversee the progression of ADC batch sizes from milligram to >100 g scales to support not only PD optimization, but analytical and formulation development, DS/DP stability studies, and in vivo experiments (including critical GLP tox studies) for both IND- and BLA-stage activities .

• Lead the multi-gram scale purification optimization for both antibody intermediates and ADCs via ultrafiltration/diafiltration (UF/DF), and, if required , preparative chromatography or other approaches.

• Fulfill role as ADC DS subject matter expert (SME) on both internal cross-functional CMC teams and for external CDMO partners to ensure alignment on ADC program goals, deliverables, and objectives . Occasional travel to advise and oversee Development and GMP manufacturing processes will be expected.

<li data-leveltext="·" data-font="Symbol" data-listid="2" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469